September 4-7 2018
Boston, MA


Twitter logo for website footers 2

Speakers

Expand/Collapse

James Noble
CEO
Adaptimmune

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Mark Dudley
Senior Vice President of Bioprocessing
Adaptimmune

Eric Van Hofe
President
AffyImmune Therapeutics

Paul Rennert
President & CSO
Aleta Biotherapeutics

David Chang
CEO
Allogene Therapeutics

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Jim Faulkner
SVP & Head of Product Delivery
Autolus

Jamie Margolis
Director, Product Development Operation
Be The Match BioTherapies

Peter Olagunju
VP
bluebird bio

Philip Gregory
CSO
bluebird bio

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Rick Morgan
Vice President of Immunotherapy
bluebird bio

Andy Philips
CEO
C4 Therapeutics

Jennifer Fillman
Vice President and General Manager, Specialty Services
Cardinal Health Specialty Solutions

Day Two

Thursday September 6th 2018

10.00 | Driving Adoption of Your CAR-T Therapy with a Proven Logistics and Access Strategy

Steven Kelly
President and CEO
CARMA Therapeutics

Zonghai Li
Founder, CEO and CSO
CARSgen Therapeutics

Stefanos Theoharis
SVP, Partnering and Corporate Development
Cell Medica

André Choulika
CEO
Cellectis

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

David Sourdive
EVP, Technical Operations
Cellectis

Benham Badie
Professor & Chief, Division of Neurosurgery & Director
City of Hope Medical Center

Mike Stella
Chief Business Officer and Director
Cognate

Mark Sawicki
Chief Commercial Officer
Cryoport

Charles Sentman

Dartmouth Geisel School of Medicine

Chris Leamon
Vice President of Research
Endocyte

Edmund Pezalla
CEO & Founder
Enlightenment Bioconsult LLC

Bijan Nejadnik
CMO
Eureka Therapeutics

Cheng Liu
CEO
Eureka Therapeutics

Bob Valamehr
VP, Cancer Immunotherapy
Fate Therapeutics

Jim Beitel
SVP, Corporate Development
Fate Therapeutics

Richard Grant
Chief Product Officer
FloDesign Sonics

Philip Vanek
GM, Cell Therapy Growth Strategy
GE Healthcare

Day Two

Thursday September 6th 2018

09.30 | Smart, Closed & Connected Solutions for Cell Therapy Production

Robert Preti
CEO & President
Hitachi Chemical Advanced Therapeutics Solutions

Cameron Durrant
Chairman and Chief Executive Officer
Humanigen, Inc.

Eileen Higham
Head of Analytical and Process Development
Juno Therapeutics

Ali Mohamed
VP, CMC
Immatics

Steffen Walter
Co-Founder & CSO
Immatics

Sean MacKay
CEO
Isoplexis

John Rossi
Director, Translational Sciences
Kite Pharma

Peter Emtage
Global Head of Cell Therapy
Kite, a Gilead Company

Yuan Xu
CEO
Legend Biotech

Bala Manian
Executive Chairman
LeukoDx

Nina Bauer
Commercial Development Lead, Autologous Cell Therapy
Lonza

Nina Bauer is the Commercial Development Lead of Lonza’s autologous cell therapy business. She is in charge of establishing novel manufacturing technologies to remove bottlenecks and enable commercial services for patient-scale therapies. Prior to joining Lonza, Nina held business development roles at the Cell Therapy Catapult (London), and the University of Edinburgh, and worked as Life Science Consultant for regenerative medicine businesses. She holds a PhD in Neuroscience from the University of Oldenburg (GER), an MBA from the University of Edinburgh (UK), and conducted post-doctoral research at the Weizman Institute (ISR), Salk Institute (USA), and the University of Edinburgh (UK).

Saad Kenderian
Director, T cell Engineering Program
Mayo Clinic

Dolores Schendel
CEO & CSO
Medigene

Isabelle Riviere
Director, Cell Therapy and Cell Engineering Facility
Memorial Sloan Kettering Cancer Center

Boro Dropulic
CSO & General Manager, Lentigen Technology
Miltenyi Biotec Company

Sadik Kassim
Chief Scientific Officer
Mustang Bio

James Kochenderfer
Investigator, Experimental Transplantation & Immunology Branch
National Cancer Institute

Steven Feldman
Director, Surgery Branch Vector Production Facility
National Cancer Institute (NCI) in NIH

Mario Marcondes
Medical Director, Clinical Development
Nektar Therapeutics

Rona Singer Weinberg
Director, Cellular Therapy Laboratory Director, MPD Laboratory
New York Blood Center, Blood Centers of America

Koji Tamada
CSMO
Noile-Immune Biotech

Rodney Rietze
Enabling Technology and Strategic Development
Novartis

Samuele Butera
Global Cell & Gene Therapies Business Leader
Novartis

Day Two

Thursday September 6th 2018

17.15 | Closing Ceremony Panel Discussion: Lessons Learnt from the Leaders

Therese Choquette
Analytical Project Leader, Cell and Gene Therapy Development and Manufacturing
Novartis

Yajin Ni
Director, CART Manufacturing Process Development
Pfizer

Vita Golubovskaya
Director R&D, BD
Promab Biotechnologies

Scott Ohanesian
Senior VP of Commercial Operations, Clinical Trial Logistics
QuickSTAT, a Quick Company

Barbra Sasu
VP, Head of Biology & CAR-T Lead
Rinat/Pfizer

Gary Lee
Vice President, Cell Therapy
Sangamo Biosciences

Michael Leek
Chief Executive Officer
TC Biopharm

Robert Hofmeister
CSO
TCR2 Therapeutics

John Connolly
Chief Scientific Officer
Tessa Therapeutics

John Ellis
Senior Director, Technical Services
ThermoGenesis

Usman Azam
President & CEO
Tmunity

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Thomas Andresen
Co-founder and CSO
Torque Therapeutics

Jeffrey Tice
Professor of Medicine, Division of General Internal Medicine
University of California, San Francisco

Avery Posey

University of Pennsylvania

Bruce Levine
Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF)
University of Pennsylvania

Carl June
Professor & Director Translational Research, Abramson Cancer Center
University of Pennsylvania

Day One

Wednesday September 5th 2018

08.15 | Opening Ceremony

David Porter
Director of Cell Therapy and Transplant
University of Pennsylvania

Roderick O’ Connor
Instructor, Center for Cellular Immunotherapies
University of Pennsylvania School of Medicine

Simon Lacey
Director Translational and Correlative Studies Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania

Miguel Forte
Chief Executive Officer
Zelluna Immunotherapy